<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2023/01/56612299-m.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2023/01/56612299-m.jpg"/></p>
<p>礼来公司（纽约证券交易所：LLY）于周二获得了美国食品药品监督管理局对其阿尔茨海默病药物的批准。</p>
<p>这一进展意义重大，因为它扩大了治疗这种影响近 700 万美国人的神经系统疾病的选择。</p>
<p>截至目前，礼来公司股价为 910 美元。自 2024 年初以来，这家制药公司的股价已上涨超过 50%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Eli-Lilly-stock-1024x535.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Eli-Lilly-stock-1024x535.jpg"/></p>
<h2>Kinsula 新闻对礼来公司股票是否重要？</h2>
<p>阿尔茨海默病是 65 岁以上美国人死亡的前五大原因之一。</p>
<p>更重要的是，预计到 2050 年，美国患有这种消耗大脑的疾病的患者数量将达到 1300 万，这凸显了像礼来公司的多那奈单抗这样的有效治疗的迫切需求。</p>
<p>获得其阿尔茨海默病药物的 FDA 批准对礼来公司来说是一项重大突破。这是因为美国监管机构去年拒绝了多那奈单抗，称数据不足。该批准在 2024 年 3 月面临意外延迟。</p>
<p>阿尔茨海默病的消息可能会推动礼来公司股票的下一波上涨，今年以来，该股票在其减肥药需求强劲的支撑下表现优异。</p>
<p>许多人预计 LLY 将成为首个市值达到 1.0 万亿美元的医疗保健公司。</p>
<h2>礼来公司将直接与生物新领域竞争</h2>
<p>在其咨询小组得出多那奈单抗的益处大于风险的结论后不久，FDA 对礼来公司的阿尔茨海默病药物进行了全面批准。</p>
<p>这家市值 8700 亿美元的巨头现在将直接与生物新领域竞争，后者在 2023 年夏季获得了其阿尔茨海默病药物 Leqembi 的批准。多那奈单抗将成为美国市场上第三种治疗阿尔茨海默病的药物。</p>
<p>Leqembi 和多那奈单抗都是针对淀粉样斑块的单克隆抗体。两者都不是绝对的治愈方法，而且都可能存在潜在的安全问题，包括有时可能致命的脑部肿胀和出血。</p>
<p>例如，在礼来公司晚期研究中，有三名患者死于与淀粉样成像异常相关的脑部异常。观看视频: https://www.youtube.com/embed/gO2ShFRucNM?feature=oembed</p>
<h2>礼来公司的其他最新发展</h2>
<p>请注意，礼来公司将其阿尔茨海默病药物推广为 “Kisunla”。今年 6 月，前 FDA 专员斯科特·戈特利布表示，阿尔茨海默病对 LLY 来说可能是一个非常大的领域。</p>
<p>多那奈单抗的消息是在这家纽约上市公司宣布第三季度每股 1.30 美元股息几周后发布的。</p>
<p>上个月，它还与 OpenAI 合作，利用人工智能发现新药物并治疗耐药细菌。LLY 首席运营官布拉德·莱特卡普当时表示：</p>
<p>先进的人工智能有潜力在制药领域带来创新突破，我们致力于与行业领导者合作，为患者带来实实在在的好处。</p>
<p>本文来源：Invezz，原文链接：Eli Lilly receives FDA approval for its Alzheimer's drug Kinsula</p>

礼来

<p>礼来（Eli Lilly）已获得 FDA 批准其阿尔茨海默病药物 Kinsula，扩大了治疗这种神经系统疾病的选择。这一批准对礼来来说是一项重大突破，因为该药物此前由于数据不足而被拒绝。随着阿尔茨海默病患者数量的增加和潜在的市场需求，这一消息可能会对礼来的股价产生重大影响</p>

<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2023/01/56612299-m.jpg" alt="" original-src="https://invezz.com/wp-content/uploads/2023/01/56612299-m.jpg"/></p>
<p>Eli Lilly &amp; Co (NYSE: LLY) received approval for its Alzheimer’s drug from the Food &amp; Drug Administration on Tuesday.</p>
<div class="lb-trans"><p>礼来公司（纽约证券交易所：LLY）于周二获得了美国食品药品监督管理局对其阿尔茨海默病药物的批准。</p>
</div><p>The development is significant as it expands treatment options for the neurological disorder that affects close to 7 million Americans.</p>
<div class="lb-trans"><p>这一进展意义重大，因为它扩大了治疗这种影响近 700 万美国人的神经系统疾病的选择。</p>
</div><p>At the time of writing, Eli Lilly shares are exchanging hands at $910. The pharma stock has gained more than 50% since the start of 2024.</p>
<div class="lb-trans"><p>截至目前，礼来公司股价为 910 美元。自 2024 年初以来，这家制药公司的股价已上涨超过 50%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Eli-Lilly-stock-1024x535.jpg" alt="" original-src="https://invezz.com/wp-content/uploads/2024/07/Eli-Lilly-stock-1024x535.jpg"/></p>
<h2>Is Kinsula news significant for Eli Lilly stock?</h2>
<div class="lb-trans"><h2>Kinsula 新闻对礼来公司股票是否重要？</h2>
</div><p>Alzheimer’s is among the top five causes of deaths for Americans aged more than 65.</p>
<div class="lb-trans"><p>阿尔茨海默病是 65 岁以上美国人死亡的前五大原因之一。</p>
</div><p>More importantly, the number of patients suffering from this mind-wasting disease is expected to hit 13 million in the United States by 2050, which underscores the urgent need for effective treatments like Lilly’s donanemab.</p>
<div class="lb-trans"><p>更重要的是，预计到 2050 年，美国患有这种消耗大脑的疾病的患者数量将达到 1300 万，这凸显了像礼来公司的多那奈单抗这样的有效治疗的迫切需求。</p>
</div><p>Securing FDA approval for its Alzheimer’s drug is a major breakthrough for Eli Lilly. That’s because the U.S. regulator cited insufficient data as it rejected donanemab last year. The approval faced unexpected delay in March of 2024 as well.</p>
<div class="lb-trans"><p>获得其阿尔茨海默病药物的 FDA 批准对礼来公司来说是一项重大突破。这是因为美国监管机构去年拒绝了多那奈单抗，称数据不足。该批准在 2024 年 3 月面临意外延迟。</p>
</div><p>The Alzheimer’s news may unlock the next leg up in Eli Lilly stock that has outperformed this year on the back of strong demand for its weight-loss drug.</p>
<div class="lb-trans"><p>阿尔茨海默病的消息可能会推动礼来公司股票的下一波上涨，今年以来，该股票在其减肥药需求强劲的支撑下表现优异。</p>
</div><p>Many expect LLY to be the first healthcare name to hit $1.0 trillion in valuation.</p>
<div class="lb-trans"><p>许多人预计 LLY 将成为首个市值达到 1.0 万亿美元的医疗保健公司。</p>
</div><h2>Lilly to compete directly with Biogen</h2>
<div class="lb-trans"><h2>礼来公司将直接与生物新领域竞争</h2>
</div><p>FDA’s full approval for Lilly’s Alzheimer’s drug arrives shortly after its advisory panel concluded the benefits of donanemab outweigh the risks.</p>
<div class="lb-trans"><p>在其咨询小组得出多那奈单抗的益处大于风险的结论后不久，FDA 对礼来公司的阿尔茨海默病药物进行了全面批准。</p>
</div><p>The $870 billion behemoth will now compete directly with Biogen that secured approval for Leqembi (its Alzheimer’s drug) in summer of 2023. Donanemab is set to become the third treatment for Alzheimer’s to hit the market in the U.S.</p>
<div class="lb-trans"><p>这家市值 8700 亿美元的巨头现在将直接与生物新领域竞争，后者在 2023 年夏季获得了其阿尔茨海默病药物 Leqembi 的批准。多那奈单抗将成为美国市场上第三种治疗阿尔茨海默病的药物。</p>
</div><p>Both Leqembi and Donanemab are monoclonal antibodies that target amyloid plaques. Neither is a definitive cure and both can have potential safety concerns including brain swelling and bleeding that can sometimes be fatal.</p>
<div class="lb-trans"><p>Leqembi 和多那奈单抗都是针对淀粉样斑块的单克隆抗体。两者都不是绝对的治愈方法，而且都可能存在潜在的安全问题，包括有时可能致命的脑部肿胀和出血。</p>
</div><p>Three patients, for example, in the late-stage study of Eli Lilly died due to ARIA (amyloid-related imaging abnormalities).Watch here: https://www.youtube.com/embed/gO2ShFRucNM?feature=oembed</p>
<div class="lb-trans"><p>例如，在礼来公司晚期研究中，有三名患者死于与淀粉样成像异常相关的脑部异常。观看视频: https://www.youtube.com/embed/gO2ShFRucNM?feature=oembed</p>
</div><h2>Other recent developments related to LLY</h2>
<div class="lb-trans"><h2>礼来公司的其他最新发展</h2>
</div><p>Note that Eli Lilly will market its Alzheimer’s drug as “Kisunla”.In June, former FDA commissioner Dr Scott Gottlieb said Alzheimer’s could be a very big category for LLY.</p>
<div class="lb-trans"><p>请注意，礼来公司将其阿尔茨海默病药物推广为 “Kisunla”。今年 6 月，前 FDA 专员斯科特·戈特利布表示，阿尔茨海默病对 LLY 来说可能是一个非常大的领域。</p>
</div><p>The donanemab news arrives a couple weeks after the New York listed firm announced $1.30 a share of dividend for the third quarter.</p>
<div class="lb-trans"><p>多那奈单抗的消息是在这家纽约上市公司宣布第三季度每股 1.30 美元股息几周后发布的。</p>
</div><p>It also teamed up with OpenAI last month to tap on artificial intelligence to discover novel medicines and treat drug-resistant bacteria. Brad Lightcap – the chief operating officer of LLY said at the time:</p>
<blockquote>
</blockquote>
<div class="lb-trans"><p>上个月，它还与 OpenAI 合作，利用人工智能发现新药物并治疗耐药细菌。LLY 首席运营官布拉德·莱特卡普当时表示：</p>
</div><p>Advanced AI has the potential to deliver innovative breakthroughs in pharma, and we’re committed to working together with industry leaders to deliver tangible benefits for patients.</p>
<div class="lb-trans"><p>先进的人工智能有潜力在制药领域带来创新突破，我们致力于与行业领导者合作，为患者带来实实在在的好处。</p>
</div><p>The post Eli Lilly receives FDA approval for its Alzheimer's drug Kinsula appeared first on Invezz</p>
<div class="lb-trans"><p>本文来源：Invezz，原文链接：Eli Lilly receives FDA approval for its Alzheimer's drug Kinsula</p>
</div>

礼来的阿尔茨海默症药物 Kinsula 获得 FDA 批准